中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2014年
29期
14-14,15
,共2页
高血压%持续性房颤%缬沙坦%阿托伐他汀
高血壓%持續性房顫%纈沙坦%阿託伐他汀
고혈압%지속성방전%힐사탄%아탁벌타정
Hypertention%Persistent atrial ifbrillation%Valsartan%Atorvastatin
目的:探讨缬沙坦和阿托伐他汀治疗高血压病合并持续性房颤的疗效。方法选取来我院的高血压病合并持续性房颤患者40例,随机分为两组,每组20例,为实验组和对照组。对照组给予常规的抗凝治疗,服用阿托伐他汀同时服用硝苯地平缓释片;实验组则在对照组的基础上服用缬沙坦治疗。观察两组患者的血压变化、hs-CRP、LAD以及LVMI。结果两组患者治疗前血压无明显差异(P>0.05),治疗后两组患者血压觉得到明显改善,但实验组治疗效果与对照组相比,治疗效果更加良好(P<0.05)。两组患者治疗前hs-CRP、LAD以及LVMI均无显著差异(P>0.05),治疗后,实验组治疗效果明显优于对照组(P<0.05)。结论缬沙坦和阿托伐他汀联合治疗高血压病合并持续性房颤效果明显较之单独使用一种药物效果好,值得临床使用及进一步探讨。
目的:探討纈沙坦和阿託伐他汀治療高血壓病閤併持續性房顫的療效。方法選取來我院的高血壓病閤併持續性房顫患者40例,隨機分為兩組,每組20例,為實驗組和對照組。對照組給予常規的抗凝治療,服用阿託伐他汀同時服用硝苯地平緩釋片;實驗組則在對照組的基礎上服用纈沙坦治療。觀察兩組患者的血壓變化、hs-CRP、LAD以及LVMI。結果兩組患者治療前血壓無明顯差異(P>0.05),治療後兩組患者血壓覺得到明顯改善,但實驗組治療效果與對照組相比,治療效果更加良好(P<0.05)。兩組患者治療前hs-CRP、LAD以及LVMI均無顯著差異(P>0.05),治療後,實驗組治療效果明顯優于對照組(P<0.05)。結論纈沙坦和阿託伐他汀聯閤治療高血壓病閤併持續性房顫效果明顯較之單獨使用一種藥物效果好,值得臨床使用及進一步探討。
목적:탐토힐사탄화아탁벌타정치료고혈압병합병지속성방전적료효。방법선취래아원적고혈압병합병지속성방전환자40례,수궤분위량조,매조20례,위실험조화대조조。대조조급여상규적항응치료,복용아탁벌타정동시복용초분지평완석편;실험조칙재대조조적기출상복용힐사탄치료。관찰량조환자적혈압변화、hs-CRP、LAD이급LVMI。결과량조환자치료전혈압무명현차이(P>0.05),치료후량조환자혈압각득도명현개선,단실험조치료효과여대조조상비,치료효과경가량호(P<0.05)。량조환자치료전hs-CRP、LAD이급LVMI균무현저차이(P>0.05),치료후,실험조치료효과명현우우대조조(P<0.05)。결론힐사탄화아탁벌타정연합치료고혈압병합병지속성방전효과명현교지단독사용일충약물효과호,치득림상사용급진일보탐토。
Objective To explore the curative effect about valsartan and atorvastatin to treat hypertention with persistent atrial ifbrillation. Methods Choose 40 patients with hypertention and persistent atrial ifbrillation who came to our hospital last year, randomly dividing into two groups, the experimental group and the control group. The control group was treated with atorvastatin and nifedipine zyban, following with anticoagulation therapy. The experimental group with the control groups the same, besides the valsartan taken. Then, observe the changes of two groups of patients with blood pressure, hs-CRP, LAD and LVMI. Results There is no difference in blood pressure between the two groups of patients before treatment, but the treatment effect of the experimental group is better than the control posttreatment. And there is also no difference in hs-CRP, LAD and LVMI between the two groups of patients before treatment, but the treatment effect of the experimental group is also better than the control posttreatment. Conclusion The combination of valsartan and atorvastatin is better than the use of only one kind of drugs above, and it is worthy to apply and further discuss in clinical.